Detalhe da pesquisa
1.
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages.
Immunity
; 56(1): 162-179.e6, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630914
2.
Selective targeting of IL2Rßγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC.
Cell Rep Med
; 4(8): 101150, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37586327